Department of Biochemistry, Chosun University School of Medicine, Gwangju 61452, Republic of Korea.
Surgery Department, Chang Surgical Clinic, Gwangju 62274, Republic of Korea.
Mol Cells. 2024 Jun;47(6):100075. doi: 10.1016/j.mocell.2024.100075. Epub 2024 May 31.
Excessive blood vessel wall thickening, known as intimal hyperplasia, can result from injury or inflammation and increase the risk of vascular diseases. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) plays key roles in tumor surveillance, autoimmune diseases, and apoptosis; however, its role in vascular stenosis remains controversial. Treatment with recombinant isoleucine zipper hexamerization domain soluble TRAIL (ILz(6):TRAIL) significantly inhibited the progression of neointimal hyperplasia (NH) induced by anastomosis of the carotid artery and jugular vein dose dependently, and adenovirus expressing secretable ILz(6):TRAIL also inhibited NH induced by balloon injury in the femoral artery of rats. This study demonstrated the preventive and partial regressive effects of ILz(6):TRAIL on anastomosis of the carotid artery and jugular vein- or balloon-induced NH.
血管壁过度增厚,即内膜增生,可能由损伤或炎症引起,并增加血管疾病的风险。肿瘤坏死因子相关凋亡诱导配体(TRAIL)在肿瘤监测、自身免疫性疾病和细胞凋亡中发挥关键作用;然而,其在血管狭窄中的作用仍存在争议。用重组异亮氨酸拉链六聚体结构域可溶性 TRAIL(ILz(6):TRAIL)治疗可显著抑制颈动脉和颈静脉吻合诱导的新生内膜增生(NH)的进展,呈剂量依赖性,表达可分泌 ILz(6):TRAIL 的腺病毒也可抑制大鼠股动脉球囊损伤诱导的 NH。本研究证明了 ILz(6):TRAIL 对颈动脉和颈静脉吻合或球囊诱导的 NH 的预防和部分消退作用。